Expansion opportunities Viatis (Viataris) has recent partnerships and licensing deals with Opus Genetics for exclusive U.S. commercialization rights, signaling a growth trajectory in specialty ophthalmology and presbyopia indications that present cross-sell opportunities for contract manufacturing, supply chain services, and regional market expansion.

Regulatory action risk FDA Class III recall of a telmisartan-amlodipine product highlights quality assurance and compliant manufacturing needs. This creates a potential services opportunity in pharmacovigilance, remediation, and manufacturing process optimization for Viatris and its suppliers.

Innovation pipeline Active licensing and development deals with Opus Genetics for phentolamine ophthalmic solution and PS treatments, plus potential fast-track meloxicam variants, indicate ongoing pipeline growth that could benefit from collaboration on formulation development, analytics, and scalable manufacturing processes.

Global engagement cardiovascular Masterclass events and regional health dialogues show Viatris’ active engagement with healthcare professionals, presenting a doorway for continuing education partnerships, sponsored medical events, and targeted outreach to ophthalmology, cardiovascular, and primary care segments.

Recognition & scale Forbes and Statista naming Viatris among World’s Best Employers reinforces a strong employer brand and stability, suggesting opportunities to position as a preferred supplier of validated, compliant, scalable pharmaceutical manufacturing and IT-enabled services to support large-scale operations.